ReviewFuture oncology (London, England)2009
EGF-receptor regulation of matrix metalloproteinases in epithelial ovarian carcinoma.
Review in Future oncology (London, England), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 35 citations in OpenAlex.
- Multiplicative Effects of Essential Oils and Other Active Components on Skin Tissue and Skin Cancers.International journal of molecular sciences · 2024Review
- Molecular pathways and therapeutic targets linked to triple-negative breast cancer (TNBC).Molecular and cellular biochemistry · 2024Review
- Identification of EGFR as a Biomarker in Saliva and Buccal Cells from Oral Submucous Fibrosis Patients-A Baseline Study.Diagnostics (Basel, Switzerland) · 2022Article
- Aloysia Citrodora Essential Oil Inhibits Melanoma Cell Growth and Migration by Targeting HB-EGF-EGFR Signaling.International journal of molecular sciences · 2021Article
- Article
- Investigations on the Role of the Fibrinolytic Pathway on Outflow Facility Regulation.Investigative ophthalmology & visual science · 2019Article
- Epidermal growth factor receptor-mediated regulation of matrix metalloproteinase-2 and matrix metalloproteinase-9 in MCF-7 breast cancer cells.Molecular and cellular biochemistry · 2019Article
- Agonist-Biased Signaling via Matrix Metalloproteinase-9 Promotes Extracellular Matrix Remodeling.Cells · 2018Review
- BCAT1 expression associates with ovarian cancer progression: possible implications in altered disease metabolism.Oncotarget · 2015Article
- Protein-bound uremic toxins induce tissue remodeling by targeting the EGF receptor.Journal of the American Society of Nephrology : JASN · 2015Article
- Contributions of the Epidermal Growth Factor Receptor to Acquisition of Platinum Resistance in Ovarian Cancer Cells.PloS one · 2015Article
- Epidermal growth factor receptor gene polymorphisms are associated with prognostic features of breast cancer.BMC cancer · 2014Article
- Accelerated wound closure in vitro by fibroblasts from a subgroup of cleft lip/palate patients: role of transforming growth factor-α.PloS one · 2014Article
- Photoimmunotherapy and irradiance modulation reduce chemotherapy cycles and toxicity in a murine model for ovarian carcinomatosis: perspective and results.Israel journal of chemistry · 2012Article
- A positive feedback loop between HER2 and ADAM12 in human head and neck cancer cells increases migration and invasion.Oncogene · 2012Article
- Increased DNA methyltransferase activity and DNA methylation following Epidermal Growth Factor stimulation in ovarian cancer cells.Epigenetics · 2012Article
- Differential downregulation of e-cadherin and desmoglein by epidermal growth factor.Dermatology research and practice · 2012Article
- Revisiting the role of antiandrogen strategies in ovarian cancer.The oncologist · 2011Review
- Targeting the EGF receptor for ovarian cancer therapy.Journal of oncology · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
Ovarian carcinoma is most frequently detected when disease has already disseminated intra-abdominally, resulting in a 5-year survival rate of less than 20% owing to complications of metastasis. Peritoneal ascites is often present, establishing a unique microenvironmental niche comprised of tumor and inflammatory cells, along with a wide range of bioactive soluble factors, several of which stimulate the EGF-receptor (EGFR). Elevated EGFR is associated with less favorable disease outcome in ovarian cancer, related in part to EGFR activation of signaling cascades that lead to enhanced matrix metalloproteinase expression and/or function. The available data suggest that modulating the expression or activity of the EGFR and/or matrix metalloproteinases offers opportunity for targeted intervention in patients with metastatic disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.